newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board

EIKN
  • Eikon Therapeutics (NASDAQ: EIKN) appointed Johnny Bennett, Ph.D., Vice President & Head of Discovery Chemistry at Merck Research Laboratories, to its Scientific Advisory Board.
  • The appointment strengthens the ongoing relationship between Eikon and Merck, which previously supplied KEYTRUDA for trials of EIK1001 and EIK1005 and participated in Eikon's initial public offering.
  • Dr. Bennett is a Scottish native who earned degrees from Heriot-Watt University & co-discovered sugammadex (Bridion) during his tenure at N.V. Organon.
  • He received the American Chemical Society Heroes of Chemistry Award & the Royal Society of Chemistry Malcolm Campbell Memorial Award for his contributions to medical sciences.
  • Dr. Bennett relocated to the US in 2011, joined Merck, & rose through leadership roles to become Vice President in 2022, previously serving as interim Head of Discovery Oncology in 2024.
  • He joins a distinguished board including Nobel laureates Eric Betzig, Ph.D. & Thomas Cech, Ph.D., co-founders Eric Betzig & Robert Tjian, Ph.D., & experts Trey Ideker, Ph.D. & Wendy B. Young, Ph.D.
  • Eikon is a late-stage clinical biopharmaceutical company focused on oncology, utilizing its proprietary single molecule tracking platform to develop innovative cancer therapies.
  • The press release includes standard forward-looking statements regarding Eikon's product candidates, financial performance, & development milestones subject to various risks & uncertainties.